Kevin Kerber

Oct 30, 2023 | n.neurology.org | Chun Chieh Lin |Chloë Hill |Kevin Kerber

GlossaryALS=amyotrophic lateral sclerosis; AUC=area under the curve; E/M=evaluation and management; HRR=hospital referral region; ICC=intraclass correlation coefficient; IQR=interquartile range; MBSF=Master Beneficiary Summary File; MS=multiple sclerosis; NPPES=National Plan and Provider Enumeration System; PCP=primary care provider; RUCA=Rural-Urban Commuting AreaFootnotesGo to Neurology.org/N for full disclosures.

Oct 10, 2023 | myumi.ch | James Burke |Kevin Kerber |Kenneth M. Langa |Roger L Albin

REQUIREMENTSYou must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information. Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

Oct 9, 2023 | n.neurology.org | James Burke |Kevin Kerber |Kenneth M. Langa |Roger L Albin

REQUIREMENTSYou must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information. Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

Sep 13, 2023 | n.neurology.org | Chun Chieh Lin |Chloë Hill |Kevin Kerber |James Burke

AbstractBackground and Objectives: The density of neurologists within a given geographic region varies greatly across the US. We aimed to measure patient travel distance and travel time to neurologist visits, across neurologic conditions and subspecialties. Our secondary goal was to identify factors associated with long-distance travel for neurologic care. Methods: We performed a cross-sectional analysis using a 2018 Medicare sample of patients with at least one outpatient neurologist visit.

Jul 21, 2023 | n.neurology.org | James Burke |Kevin Kerber |Kenneth M. Langa |Roger L Albin

AbstractLecanemab, a novel amyloid-sequestering agent, recently received accelerated FDA approval for the treatment of mild Dementia due to Alzheimer Disease (AD) and Mild Cognitive Impairment (MCI). Approval was based on a large Phase 3 trial, Clarity, which demonstrated reductions in amyloid plaque burden and cognitive decline with lecanemab.